Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France's Dynacure Gets VC Backing To Progress Antisense Candidate For Myopathy

Executive Summary

Clinical trials are expected to start next year with an antisense clinical candidate for the rare disease, centronuclear myopathy, developed by French start-up Dynacure as part of its collaboration with US antisense specialist Ionis Pharmaceuticals.

 

Advertisement

Related Content

Finance Watch: Global Ventures Step Into The Spotlight As The US Takes A Breather
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel